Clinical application of low-molecular-weight heparin (Fraxiparine) in rescuing venous crisis of island skin flap.
- Author:
Bing XIONG
1
;
Hua-de CHEN
;
Wen LAI
;
Shao-yi ZHENG
;
Hui GAO
;
Hui-ning BIAN
;
Zu-an LIU
;
Zhi-feng HUANG
;
Li-jun WEI
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Nadroparin; therapeutic use; Surgical Flaps; adverse effects; Treatment Outcome; Young Adult
- From: Journal of Southern Medical University 2011;31(9):1582-1584
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the clinical efficacy of low molecular weight heparin (Fraxiparine) in rescuing venous crisis of island skin flap.
METHODSOf the 73 patients with venous crisis of island skin flap, 47 received subcutaneous injection of low-molecular-weight heparin (group I) and 26 were treated with phlebotomy, local compression and topical application of unfractionated heparin solution gauze (group II).
RESULTSThe flap survival ratio was (88.46∓8.64)% in group I and (38.37∓6.53)% in group II (P<0.001). At 0, 2, and 4 h after injection of low-molecular-weight heparin, the activated partial thromboplastin time (APTT) was obviously delayed (24.28∓6.71, 41.35∓7.64 and 32.34∓6.35, respectively, P<0.01), FXa:C level was significantly decreased (152.4∓30.7, 65.8∓24.4 and 83.4∓18.4, respectively, P<0.01), while FIIa:C level underwent no obvious alterations (155.70∓31.61, 143.20∓24.75, and 143.4∓23.35, respectively, P=NS).
CONCLUSIONFraxiparine has good antithrombotic efficacy in rescuing venous crisis of island skin flap without adverse effect on systemic coagulation.
